person
Alessandro L.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
assignment
31
Clinical Trials ·
- Phase 2a Study of Tafasitamab in Adults with Primary Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia
- Long-term Safety of Asciminib in Patients With Philadelphia Chromosome-Positive CML or ALL Continuing From Parent Studies
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
248
Sites with multiple studies
Has run more than one trial at 248 of 418 partner sites.
Specializations
Myeloid Disorders
This investigator demonstrates extensive expertise in treating various myeloproliferative neoplasms and related conditions. Their research encompasses several key areas of myeloid disease management.
- Primary and Secondary Myelofibrosis
- Polycythemia Vera
- Essential Thrombocythemia
- Chronic Myeloid Leukemia
Autoimmune Conditions
The investigator focuses on treating various autoimmune hematologic disorders and related immunological conditions.
- Autoimmune Cytopenias
- Warm Autoimmune Hemolytic Anemia
- Immune Thrombocytopenia
- Chronic Neutropenic Disorders
Novel Therapeutic Approaches
The investigator specializes in evaluating innovative treatments for hematologic conditions, with particular attention to targeted therapies and novel drug combinations.
- JAK Inhibitor Therapies
- Complement Pathway Inhibition
- Nuclear Export Inhibitors
- Combination Treatment Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.